We are live on ! Find out more
GT

Glenmede Trust Portfolio holdings

AUM $20.4B
This Fund
S&P 500
This Quarter Est. Return
+7.57%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$20.9B
AUM Growth
+$1.18B
Cap. Flow
-$95.1M
Cap. Flow %
-0.46%
Top 10 Hldgs %
24.18%
Holding
1,443
New
92
Increased
575
Reduced
559
Closed
58

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$49.3M
2
IQV icon
IQVIA
IQV
+$42.7M
3
IJR icon
iShares Core S&P Small-Cap ETF
IJR
+$34.7M
4
COR icon
Cencora
COR
+$32.7M
5
VOO icon
Vanguard S&P 500 ETF
VOO
+$22.7M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$61.8M
2
PGR icon
Progressive
PGR
+$60.9M
3
ANET icon
Arista Networks
ANET
+$23.1M
4
PATH icon
UiPath
PATH
+$22.5M
5
EBAY icon
eBay
EBAY
+$22.2M

Sector Composition

Rank Sector Weight
1 Technology 23.2%
2 Healthcare 11.29%
3 Financials 10.11%
4 Consumer Discretionary 8.76%
5 Industrials 6.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FIVE icon
1401
Five Below
FIVE
$11.5B
– –
-2,063
Closed -$225K
FTI icon
1402
TechnipFMC
FTI
$28.9B
– –
-11,506
Closed -$301K
GES
1403
DELISTED
Guess Inc
GES
– –
-11,271
Closed -$230K
GLOB icon
1404
Globant
GLOB
$1.52B
– –
-2,484
Closed -$443K
GMAB icon
1405
Genmab
GMAB
$17.8B
– –
-8,698
Closed -$219K
GRFS
1406
Grifois
GRFS
$5.44B
– –
-6,874
Closed -$43.3K
HERO icon
1407
Global X Video Games & Esports ETF
HERO
$63.8M
– –
-1,832
Closed -$39.2K
IRWD icon
1408
Ironwood Pharmaceuticals
IRWD
$626M
– –
-1,395,983
Closed -$9.1M
JPEM icon
1409
JPMorgan Diversified Return Emerging Markets Equity ETF
JPEM
$384M
– –
-1,118
Closed -$60.5K
LEA icon
1410
Lear
LEA
$7.45B
– –
-25,121
Closed -$2.87M
LNW
1411
DELISTED
Light & Wonder
LNW
– –
-9,177
Closed -$962K
LYV icon
1412
Live Nation Entertainment
LYV
$42.1B
– –
-2,835
Closed -$266K
M icon
1413
Macy's
M
$6.62B
– –
-36,288
Closed -$697K
MORN icon
1414
Morningstar
MORN
$7.38B
– –
-731
Closed -$216K
MRNA icon
1415
Moderna
MRNA
$22.1B
– –
-3,463
Closed -$411K
MRVL icon
1416
Marvell Technology
MRVL
$157B
– –
-3,336
Closed -$233K
MTSI icon
1417
MACOM Technology Solutions
MTSI
$19B
– –
-2,867
Closed -$320K
NNDM
1418
Nano Dimension
NNDM
$314M
– –
-23,000
Closed -$50.6K
OXM icon
1419
Oxford Industries
OXM
$613M
– –
-4,250
Closed -$426K
PCOR icon
1420
Procore
PCOR
$7.37B
– –
-3,017
Closed -$200K
PCRX icon
1421
Pacira BioSciences
PCRX
$1.05B
– –
-367,320
Closed -$10.5M
PINC
1422
DELISTED
Premier
PINC
– –
-15,448
Closed -$288K
PRO
1423
DELISTED
PROS Holdings
PRO
– –
-16,959
Closed -$486K
PSN icon
1424
Parsons
PSN
$6.64B
– –
-13,168
Closed -$1.08M
SCHV
1425
Schwab US Large-Cap Value ETF
SCHV
$15.8B
– –
-1,560
Closed -$38.5K
54 55 56
57
58

Similar funds

SLAM
Swiss Life Asset Management Zurich $20.4B AUM 28.71% 1-Year Est. Return
EWA
EP Wealth Advisors Torrance, California $20.3B AUM
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
P
&Partners Nashville, Tennessee $20.2B AUM 19.79% 1-Year Est. Return
CI Investments Inc
CI Investments Inc Toronto, Ontario, Canada $20.6B AUM 29.22% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Glenmede Trust's Q3 2024 Portfolio in Review

As of Q3 2024, Glenmede Trust held 1,443 positions worth $20.9B, up 6% from $19.7B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Glenmede Trust's Q3 2024 filing shows 92 new, 575 increased, 559 reduced and 58 closed positions. Its largest new stake was NOV: 859,708 shares worth $13.7M. The largest sale was Vertex Pharmaceuticals, an estimated $61.8M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.

  • Glenmede Trust's largest Q3 2024 buy was NOV: 859,708 shares worth $13.7M.
  • Glenmede Trust added most to Merck in Q3 2024, an estimated $49.3M increase.
  • Glenmede Trust's biggest Q3 2024 reduction was Vertex Pharmaceuticals, cutting an estimated $61.8M.
  • Glenmede Trust fully exited Pacira BioSciences in Q3 2024, selling an estimated $10.5M.
  • Glenmede Trust's ten largest holdings make up 24% of its $20.9B portfolio in Q3 2024.
  • Glenmede Trust opened 92 new positions and closed 58 in Q3 2024.
  • Glenmede Trust's portfolio value rose 6% quarter-over-quarter to $20.9B.

Based on Glenmede Trust's 13F filing for Q3 2024, filed 13 Nov 2024.